Minggen Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minggen Hu has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Rong Liu
Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
15 shared publications - Xiu-Ping Zhang
Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
6 shared publications Jin Wang
Medical School of Chinese PLA, 100853, China
5 shared publicationsCheng-Gang Li
Medical School of Chinese PLA, 100853, China
4 shared publicationsKuang Chen
Medical School of Chinese PLA, 100853, China
4 shared publicationsZhao-Yi Lin
Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China
4 shared publications
Latest Publications
- 3 February 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (4) , 3210-3218
Comparison of perioperative outcomes between robotic-assisted and open resection for hepatic caudate lobe hemangioma: a single-center retrospective study
Background Hepatic caudate lobe hemangiomas present unique surgical challenges due to the segment’s deep location amidst critical vasculature (IVC, portal vein, hepatic veins). The literature on hepatic caudate lobe hemangiomas remains limited, resulting in a lack of comprehensive understanding and standardized treatment protocols for this condition. By comparing the surgical and perioperative outcomes of robotic versus open complete isolated caudate lobectomy for hemangiomas, this study aims to advance our understanding and management of this disease. Methods This single-center study included 83 patients who underwent complete isolated caudate lobe hemangioma resection. Patients were allocated to two groups: the robotic liver resection group (RLR, n = 33) and the open liver resection group (OLR, n = 50). Demographic characteristics and perioperative outcomes were compared between the two cohorts. Additionally, we explored the risk factors for intraoperative bleeding and conducted a subgroup analysis of patients with BMI ≥ 25 kg/m2. Results RLR demonstrated superior outcomes vs OLR: shorter median operative time (median 105.0 vs. 192.5 min, p < 0.001), reduced blood loss (50 vs 300 mL; p < 0.001), lower transfusion rates (3.0% vs 20.0%; p < 0.05), abbreviated hospital stay (9 vs 16 days; p < 0.001), and faster recovery (postoperative stay: 5 vs 8 days; p < 0.001). Univariate analysis revealed that increased blood loss was significantly associated with surgical approach, platelet count, POD (postoperative days), operation time, and ALT level. Multivariate analysis confirmed that longer operation time was an independent predictor of increased intraoperative blood loss. High-BMI RLR patients had significantly reduced operative time (105.0 vs 231.0 min; p = 0.001), blood loss (30.0 vs 400.0 mL; p < 0.001). Conclusion Robotic isolated caudate lobectomy for hemangioma is feasible and safe, offering significant perioperative advantages over open surgery—including reduced blood loss, shorter hospitalization, and accelerated recovery—even in high-BMI patients. Robotic resection represents a viable surgical option for selected patients with hepatic caudate lobe hemangiomas.
- 3 February 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (4) , 3210-3218
Comparison of perioperative outcomes between robotic-assisted and open resection for hepatic caudate lobe hemangioma: a single-center retrospective study
Background Hepatic caudate lobe hemangiomas present unique surgical challenges due to the segment’s deep location amidst critical vasculature (IVC, portal vein, hepatic veins). The literature on hepatic caudate lobe hemangiomas remains limited, resulting in a lack of comprehensive understanding and standardized treatment protocols for this condition. By comparing the surgical and perioperative outcomes of robotic versus open complete isolated caudate lobectomy for hemangiomas, this study aims to advance our understanding and management of this disease. Methods This single-center study included 83 patients who underwent complete isolated caudate lobe hemangioma resection. Patients were allocated to two groups: the robotic liver resection group (RLR, n = 33) and the open liver resection group (OLR, n = 50). Demographic characteristics and perioperative outcomes were compared between the two cohorts. Additionally, we explored the risk factors for intraoperative bleeding and conducted a subgroup analysis of patients with BMI ≥ 25 kg/m2. Results RLR demonstrated superior outcomes vs OLR: shorter median operative time (median 105.0 vs. 192.5 min, p < 0.001), reduced blood loss (50 vs 300 mL; p < 0.001), lower transfusion rates (3.0% vs 20.0%; p < 0.05), abbreviated hospital stay (9 vs 16 days; p < 0.001), and faster recovery (postoperative stay: 5 vs 8 days; p < 0.001). Univariate analysis revealed that increased blood loss was significantly associated with surgical approach, platelet count, POD (postoperative days), operation time, and ALT level. Multivariate analysis confirmed that longer operation time was an independent predictor of increased intraoperative blood loss. High-BMI RLR patients had significantly reduced operative time (105.0 vs 231.0 min; p = 0.001), blood loss (30.0 vs 400.0 mL; p < 0.001). Conclusion Robotic isolated caudate lobectomy for hemangioma is feasible and safe, offering significant perioperative advantages over open surgery—including reduced blood loss, shorter hospitalization, and accelerated recovery—even in high-BMI patients. Robotic resection represents a viable surgical option for selected patients with hepatic caudate lobe hemangiomas.
- Open Access
- 15 May 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1-16
Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis
Non-alcoholic fatty liver disease (NAFLD) represents the most widespread liver disease globally, ranging from non-alcoholic fatty liver (NAFL) and steatohepatitis (NASH) to fibrosis/cirrhosis, with potential progression to hepatocellular carcinoma (HCC). Genome-wide association studies (GWASs) have identified several single nucleotide polymorphisms (SNPs) associated with NAFLD. However, numerous GWAS signals associated with NAFLD locate in non-coding regions, posing a challenge for interpreting their functional annotation. In this study, we utilized the Activity-by-Contact (ABC) model to construct the enhancer-gene maps of liver by integrating epigenomic data from 15 liver tissues and cell lines. We constructed the most comprehensive genome-wide regulatory maps of the liver, identifying 543,486 enhancer-gene connections, including 267,857 enhancers and 16,872 target genes. Enrichment analyses revealed that the ABC SNPs are significantly enriched in active chromatin regions and active chromatin state. By combining the ABC regulatory maps and NAFLD GWAS data, we systematically identified ABC SNPs associated with NAFLD risk. Through the functional annotations, such as pathway enrichment and drug-gene interaction analyses, we identified 6 genes (GGT1, ACTG1, SPP1, EPHA2, PROZ and SHMT1) as candidate NAFLD genes, with SHMT1 previously reported. Among the SNPs connected to the candidate genes, the ABC SNP rs2017869 (odds ratio [OR] for the C allele = 1.10, 95% CI = 1.04–1.16, P = 5.97 × 10− 4) had the highest ABC score. According to the ABC maps, rs2017869 links to GGT1, and several drugs targeting this gene, such as liothyronine, showed potential benefits to patients with NAFLD. Furthermore, we identified that another novel gene, EPHA2, may play a crucial role in NAFLD by regulating the GGT levels. Our study provides the most comprehensive ABC regulatory maps of the liver to date. This resource offers a valuable reference for identifying regulatory variants and prioritizing susceptibility genes of liver diseases, such as NAFLD.
- 15 May 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1-16
Open AccessGenome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis
Non-alcoholic fatty liver disease (NAFLD) represents the most widespread liver disease globally, ranging from non-alcoholic fatty liver (NAFL) and steatohepatitis (NASH) to fibrosis/cirrhosis, with potential progression to hepatocellular carcinoma (HCC). Genome-wide association studies (GWASs) have identified several single nucleotide polymorphisms (SNPs) associated with NAFLD. However, numerous GWAS signals associated with NAFLD locate in non-coding regions, posing a challenge for interpreting their functional annotation. In this study, we utilized the Activity-by-Contact (ABC) model to construct the enhancer-gene maps of liver by integrating epigenomic data from 15 liver tissues and cell lines. We constructed the most comprehensive genome-wide regulatory maps of the liver, identifying 543,486 enhancer-gene connections, including 267,857 enhancers and 16,872 target genes. Enrichment analyses revealed that the ABC SNPs are significantly enriched in active chromatin regions and active chromatin state. By combining the ABC regulatory maps and NAFLD GWAS data, we systematically identified ABC SNPs associated with NAFLD risk. Through the functional annotations, such as pathway enrichment and drug-gene interaction analyses, we identified 6 genes (GGT1, ACTG1, SPP1, EPHA2, PROZ and SHMT1) as candidate NAFLD genes, with SHMT1 previously reported. Among the SNPs connected to the candidate genes, the ABC SNP rs2017869 (odds ratio [OR] for the C allele = 1.10, 95% CI = 1.04–1.16, P = 5.97 × 10− 4) had the highest ABC score. According to the ABC maps, rs2017869 links to GGT1, and several drugs targeting this gene, such as liothyronine, showed potential benefits to patients with NAFLD. Furthermore, we identified that another novel gene, EPHA2, may play a crucial role in NAFLD by regulating the GGT levels. Our study provides the most comprehensive ABC regulatory maps of the liver to date. This resource offers a valuable reference for identifying regulatory variants and prioritizing susceptibility genes of liver diseases, such as NAFLD.
- 7 April 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (6) , 1428-1443
Diverse approaches and sources to derive antitumor T cell for liver cancer: a single-cell sequence based research
Introduction Despite advancements in adoptive cell therapy (ACT) for hematologic tumors, its role in solid tumors still lacks satisfactory performance, especially in Primary Liver Cancer (PLC). Therefore, further studies are needed on potential ACT sources for PLC. Methods Primary liver cancer patients who had not previously received treatment were prospectively enrolled in this research. Tumor tissues combined with lymph node and blood samples were acquired during surgery. Two different antigen-specific T-cell induction approaches were used to form cytotoxic T-cell groups from PBMCs, and antitumor T cells from tumor tissues combined with TDLNs were derived. A single-cell RNA sequence coupled with a T-cell receptor sequence was used to identify the cell subsets based on the molecular and functional properties of diverse antitumor T-cell induction approaches and sources. Results Three primary liver cancer patients were included in the present study. A total of 79,300 cell transcriptomes in 19 clusters were isolated from the clinical samples. After two different induction approaches, substantial amplification of immune cells occurred in both the CTL and CTL2 groups, with highly consistent T-cell subtypes, and selective amplification of antitumor T-cell clones in the two groups was also detected. The three-aspect comparison, which was based on the proliferation score, effect score and cytokine expression, indicated that the immunological effect of the mRNA approach was comparable to that of the multiantigen peptide approach. Finally, the antigen-specific expanded T-cell clones found in CTL, CTL2 and TAL-T cells indicated the potential of tumors combined with lymph nodes as sources for ACT. Conclusions Diverse antitumor T-cell induction approaches and sources were compared, revealing multiple effective options for antitumor T-cell derivation as a source of ACT for liver cancer. Graphical abstract
- 7 April 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (6) , 1428-1443
Diverse approaches and sources to derive antitumor T cell for liver cancer: a single-cell sequence based research
Introduction Despite advancements in adoptive cell therapy (ACT) for hematologic tumors, its role in solid tumors still lacks satisfactory performance, especially in Primary Liver Cancer (PLC). Therefore, further studies are needed on potential ACT sources for PLC. Methods Primary liver cancer patients who had not previously received treatment were prospectively enrolled in this research. Tumor tissues combined with lymph node and blood samples were acquired during surgery. Two different antigen-specific T-cell induction approaches were used to form cytotoxic T-cell groups from PBMCs, and antitumor T cells from tumor tissues combined with TDLNs were derived. A single-cell RNA sequence coupled with a T-cell receptor sequence was used to identify the cell subsets based on the molecular and functional properties of diverse antitumor T-cell induction approaches and sources. Results Three primary liver cancer patients were included in the present study. A total of 79,300 cell transcriptomes in 19 clusters were isolated from the clinical samples. After two different induction approaches, substantial amplification of immune cells occurred in both the CTL and CTL2 groups, with highly consistent T-cell subtypes, and selective amplification of antitumor T-cell clones in the two groups was also detected. The three-aspect comparison, which was based on the proliferation score, effect score and cytokine expression, indicated that the immunological effect of the mRNA approach was comparable to that of the multiantigen peptide approach. Finally, the antigen-specific expanded T-cell clones found in CTL, CTL2 and TAL-T cells indicated the potential of tumors combined with lymph nodes as sources for ACT. Conclusions Diverse antitumor T-cell induction approaches and sources were compared, revealing multiple effective options for antitumor T-cell derivation as a source of ACT for liver cancer. Graphical abstract
- 10 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (4) , 903-914
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China
Background A few studies focus on the long-term outcomes and surveillance strategies for patients with hepatocellular carcinoma (HCC) and microvascular invasion (MVI) who experience postoperative recurrence. The aim of this study was to explore the patterns and prognosis of early and late recurrence (ER and LR) after hepatectomy of such patients. Methods Consecutive patients with HCC and MVI after hepatectomy from 26 centers in China from 2009 to 2020 were included. Overall survival (OS) and post-recurrence survival (PRS) were compared using the Kaplan–Meier method and log-rank test. Results Of 2828 included patients, 1200 patients developed ER and 607 patients developed LR. Among patients with recurrence, 1166 patients had intra-hepatic recurrence as the primary site of first recurrence. The median OS times for the ER, LR, and non-recurrence groups were 20.2, 52.6, and 58.9 months, respectively. Besides, patients with ER had shorter PRS (14.3 vs. 18.9 months, p < 0.001) than LR. Compared to extra-hepatic and both intra- and extra-hepatic recurrence, intra-hepatic recurrence had better OS and PRS (p < 0.001). Recurrence patients who underwent regular postoperative surveillance had longer OS (37.1 vs. 23.4 months, p < 0.001) and PRS (21.2 vs. 11.9 months, p < 0.001) compared to those with irregular surveillance. Conclusions Patients with HCC and MVI are more likely to develop ER within 1 year, and ER has a worse prognosis compared to LR. Intra-hepatic is the predominant recurrence site in ER and LR. Postoperative surveillance can improve survival outcomes in patients with recurrence. Graphical abstract
- 10 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (4) , 903-914
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China
Background A few studies focus on the long-term outcomes and surveillance strategies for patients with hepatocellular carcinoma (HCC) and microvascular invasion (MVI) who experience postoperative recurrence. The aim of this study was to explore the patterns and prognosis of early and late recurrence (ER and LR) after hepatectomy of such patients. Methods Consecutive patients with HCC and MVI after hepatectomy from 26 centers in China from 2009 to 2020 were included. Overall survival (OS) and post-recurrence survival (PRS) were compared using the Kaplan–Meier method and log-rank test. Results Of 2828 included patients, 1200 patients developed ER and 607 patients developed LR. Among patients with recurrence, 1166 patients had intra-hepatic recurrence as the primary site of first recurrence. The median OS times for the ER, LR, and non-recurrence groups were 20.2, 52.6, and 58.9 months, respectively. Besides, patients with ER had shorter PRS (14.3 vs. 18.9 months, p < 0.001) than LR. Compared to extra-hepatic and both intra- and extra-hepatic recurrence, intra-hepatic recurrence had better OS and PRS (p < 0.001). Recurrence patients who underwent regular postoperative surveillance had longer OS (37.1 vs. 23.4 months, p < 0.001) and PRS (21.2 vs. 11.9 months, p < 0.001) compared to those with irregular surveillance. Conclusions Patients with HCC and MVI are more likely to develop ER within 1 year, and ER has a worse prognosis compared to LR. Intra-hepatic is the predominant recurrence site in ER and LR. Postoperative surveillance can improve survival outcomes in patients with recurrence. Graphical abstract
- Open Access
- 1 January 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (1) , e10-e12
Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Grading Severity of Microvascular Invasion in Hepatocellular Carcinoma: More Details, More Significance
- 1 January 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (1) , e10-e12
Open AccessGrading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Grading Severity of Microvascular Invasion in Hepatocellular Carcinoma: More Details, More Significance
- Open Access
- 27 August 2024
- Published by Wiley in Cell Proliferation
- Vol. 58 (1) , e13738
The heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus
Given the growing interest in the metabolic heterogeneity of hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). This study comprehensively analysed the metabolic heterogeneity of HCC, PVTT, and normal liver samples using multi‐omics combinations. A single‐cell RNA sequencing dataset encompassing six major cell types was obtained for integrated analysis. The optimal subtypes were identified using cluster stratification and validated using spatial transcriptomics and fluorescent multiplex immunohistochemistry. Then, a combined index based meta‐cluster was calculated to verify its prognostic significance using multi‐omics data from public cohorts. Our study first depicted the metabolic heterogeneity landscape of non‐malignant cells in HCC and PVTT at multiomics levels. The optimal subtypes interpret the metabolic characteristics of PVTT formation and development. The combined index provided effective predictions of prognosis and immunotherapy responses. Patients with a higher combined index had a relatively poor prognosis (p p =0.03). Our findings revealed both consistency and heterogeneity in the metabolism of non‐malignant cells in HCC and PVTT. The risk stratification based on cancer‐associated fibroblasts and myeloid cells conduce to predict prognosis and guide treatment. This offers new directions for understanding disease development and immunotherapy responses.
- 27 August 2024
- Published by Wiley in Cell Proliferation
- Vol. 58 (1) , e13738
Open AccessThe heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus
Given the growing interest in the metabolic heterogeneity of hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). This study comprehensively analysed the metabolic heterogeneity of HCC, PVTT, and normal liver samples using multi‐omics combinations. A single‐cell RNA sequencing dataset encompassing six major cell types was obtained for integrated analysis. The optimal subtypes were identified using cluster stratification and validated using spatial transcriptomics and fluorescent multiplex immunohistochemistry. Then, a combined index based meta‐cluster was calculated to verify its prognostic significance using multi‐omics data from public cohorts. Our study first depicted the metabolic heterogeneity landscape of non‐malignant cells in HCC and PVTT at multiomics levels. The optimal subtypes interpret the metabolic characteristics of PVTT formation and development. The combined index provided effective predictions of prognosis and immunotherapy responses. Patients with a higher combined index had a relatively poor prognosis (p p =0.03). Our findings revealed both consistency and heterogeneity in the metabolism of non‐malignant cells in HCC and PVTT. The risk stratification based on cancer‐associated fibroblasts and myeloid cells conduce to predict prognosis and guide treatment. This offers new directions for understanding disease development and immunotherapy responses.
- Open Access
- 12 April 2024
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 3 (1) , 1-11
Minimally invasive surgery is safe and effective for advanced HCC patients receiving perioperative adjuvant therapy: a real-world retrospective study
Background: Combining surgery and perioperative adjuvant therapy, including tyrosine kinase inhibitors (TKI), anti-PD-1 antibody, and interventional therapy, can prolong the survival of patients with advanced hepatocellular carcinoma (HCC). Adverse reactions to adjuvant therapy, surgical trauma, and surgical complications are challenging for this combined treatment mode. This study aims to explore whether minimally invasive hepatectomy is safe or appropriate in patients with advanced HCC. Methods: This retrospective study involved patients with advanced HCC who underwent minimally invasive surgery (MIS group, n = 31) or open surgery (OS group, n = 35) from August 2020 to April 2023 from four medical groups at two medical centers. Operation-related indicators, early postoperative complications, and postoperative drug tolerance were compared between the two groups. Results: Sixty-six patients were enrolled. Between the MIS group and the OS group, there were no significant differences in Barcelona Clinic Liver Cancer (BCLC) tumor staging (P = 0.44), surgical difficulty (P = 0.29), and R0 resection rate (P = 0.34). Compared with the OS group, the MIS group had less blood loss (101.9 mL vs. 209.0 mL, P = 0.003), shorter average operation time (165.7 min vs. 224.5 min, P = 0.000 4), shorter postoperative fasting time (1.5 d vs. 2.4 d, P = 0.002), shorter postoperative bed time (1.7 d vs. 3.0 d, P < 0.0001) and length of hospital stay (7.1 d vs. 9.4 d, P = 0.001), lower incidence of complication (Clavien-Dindo grade II–III, P = 0.03), better nutritional status, and earlier postoperative adjuvant treatment. Conclusion: Minimally invasive hepatectomy is safe for patients with advanced HCC after conversion therapy and may improve tolerance to combination treatment relative to open surgery. Graphical
- 12 April 2024
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 3 (1) , 1-11
Open AccessMinimally invasive surgery is safe and effective for advanced HCC patients receiving perioperative adjuvant therapy: a real-world retrospective study
Background: Combining surgery and perioperative adjuvant therapy, including tyrosine kinase inhibitors (TKI), anti-PD-1 antibody, and interventional therapy, can prolong the survival of patients with advanced hepatocellular carcinoma (HCC). Adverse reactions to adjuvant therapy, surgical trauma, and surgical complications are challenging for this combined treatment mode. This study aims to explore whether minimally invasive hepatectomy is safe or appropriate in patients with advanced HCC. Methods: This retrospective study involved patients with advanced HCC who underwent minimally invasive surgery (MIS group, n = 31) or open surgery (OS group, n = 35) from August 2020 to April 2023 from four medical groups at two medical centers. Operation-related indicators, early postoperative complications, and postoperative drug tolerance were compared between the two groups. Results: Sixty-six patients were enrolled. Between the MIS group and the OS group, there were no significant differences in Barcelona Clinic Liver Cancer (BCLC) tumor staging (P = 0.44), surgical difficulty (P = 0.29), and R0 resection rate (P = 0.34). Compared with the OS group, the MIS group had less blood loss (101.9 mL vs. 209.0 mL, P = 0.003), shorter average operation time (165.7 min vs. 224.5 min, P = 0.000 4), shorter postoperative fasting time (1.5 d vs. 2.4 d, P = 0.002), shorter postoperative bed time (1.7 d vs. 3.0 d, P < 0.0001) and length of hospital stay (7.1 d vs. 9.4 d, P = 0.001), lower incidence of complication (Clavien-Dindo grade II–III, P = 0.03), better nutritional status, and earlier postoperative adjuvant treatment. Conclusion: Minimally invasive hepatectomy is safe for patients with advanced HCC after conversion therapy and may improve tolerance to combination treatment relative to open surgery. Graphical
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (19) , 6223-6231
Deep Neural Network and Radiomics-based Magnetic Resonance Imaging System for Predicting Microvascular Invasion in Hepatocellular Carcinoma
Background: Accurate preoperative evaluation of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is crucial for surgeons to make informed decisions regarding appropriate treatment strategies. However, it continues to pose a significant challenge for radiologists. The integration of computer-aided diagnosis utilizing deep learning technology emerges as a promising approach to enhance the prediction accuracy.
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (19) , 6223-6231
Open AccessDeep Neural Network and Radiomics-based Magnetic Resonance Imaging System for Predicting Microvascular Invasion in Hepatocellular Carcinoma
Background: Accurate preoperative evaluation of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is crucial for surgeons to make informed decisions regarding appropriate treatment strategies. However, it continues to pose a significant challenge for radiologists. The integration of computer-aided diagnosis utilizing deep learning technology emerges as a promising approach to enhance the prediction accuracy.
- Open Access
- 16 November 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (2) , 660-667
Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study
Background: Robotic hepatectomy (RH) is currently widely accepted and it is associated with some benefits when compared to open hepatectomy (OH). However, whether such benefits can still be achieved for patients with large hepatocellular carcinoma (HCC) remain unclear. This study aimed to evaluate the short-term and long-term outcomes of patients undergoing RH or OH. Methods: Perioperative and survival data from patients with large HCC who underwent RH or OH between January 2010 and December 2020 were collected from eight centres. Propensity score matching (PSM) was performed to minimise potential biases. Results: Using predefined inclusion criteria, 797 patients who underwent OH and 309 patients who underwent RH were enroled in this study. After PSM, 280 patients in the robotic group had shorter operative time (median 181 vs. 201 min, PPP10 cm) who underwent RH had significantly lower estimated blood loss (median 200.0 vs. 500.0 min, PP<0.001) than those who underwent OH. Conclusion: Safety and feasibility of RH and OH for patients with large HCC were comparable. RH resulted in similar long-term survival outcomes as OH.
- 16 November 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (2) , 660-667
Open AccessShort-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study
Background: Robotic hepatectomy (RH) is currently widely accepted and it is associated with some benefits when compared to open hepatectomy (OH). However, whether such benefits can still be achieved for patients with large hepatocellular carcinoma (HCC) remain unclear. This study aimed to evaluate the short-term and long-term outcomes of patients undergoing RH or OH. Methods: Perioperative and survival data from patients with large HCC who underwent RH or OH between January 2010 and December 2020 were collected from eight centres. Propensity score matching (PSM) was performed to minimise potential biases. Results: Using predefined inclusion criteria, 797 patients who underwent OH and 309 patients who underwent RH were enroled in this study. After PSM, 280 patients in the robotic group had shorter operative time (median 181 vs. 201 min, PPP10 cm) who underwent RH had significantly lower estimated blood loss (median 200.0 vs. 500.0 min, PP<0.001) than those who underwent OH. Conclusion: Safety and feasibility of RH and OH for patients with large HCC were comparable. RH resulted in similar long-term survival outcomes as OH.